Biogen's Alzheimer's drug aducanumab implodes in a PhIII disaster -- wiping out $15B-plus in market cap - Endpoints News
- Biogen's Alzheimer's drug aducanumab implodes in a PhIII disaster -- wiping out $15B-plus in market cap Endpoints News
- Biogen shares plunge nearly 30% after ending trial for potential blockbuster Alzheimer's drug CNBC
- Biogen halts study of Alzheimer's drug, a blow to hopes for new treatment STAT
- Biogen Shares Plunge After Alzheimer’s Drug Setback Bloomberg
- Biogen to halt late-stage trial of promising Alzheimer’s drug Financial Times
- View full coverage on Google News